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T
he myc oncogene was originally identified as a transduced allele (v-myc) in the genome of avian acute leukemia virus MC29 (1) . The cellular c-myc protooncogene encodes the Myc protein, an intensively studied transcription factor with oncogenic potential (2, 3) . Myc is the central part of a transcriptional regulator network controlling the expression of up to 15% of all human genes (2, 3) , and several of the hitherto identified Myc target genes are critically involved in cellular growth, proliferation, apoptosis, metabolism, and differentiation (2, 3) . Deregulation of the c-myc gene is a frequent event in animal and human tumorigenesis, and Ϸ30% of all human cancers express Myc at elevated levels (4, 5) . Accordingly, strategies have been proposed to use inhibition of Myc function as a potential cancer therapy (6, 7) . Myc is a basic helix-loop-helix (bHLH)-Zip protein, forms heterodimers with the bHLH-Zip protein Max, binds to specific DNA sequence elements (E-boxes), and is part of a transcription factor network including additional proteins like Mad or Mnt (2) . Myc-Max heterodimers are usually implicated in transcriptional activation of distinct target genes, but Myc has also been associated with transcriptional repression (2, 3) . Known mechanisms of repression involve specific inhibition of transcriptional activators like C/EBP or Miz-1 (3, 8, 9) . Although a large number of genes activated or repressed by Myc have been identified (3, 10, 11) , the distinction between target genes that mediate the physiological functions of Myc and those that are directly relevant for tumorigenesis remains to be assessed. Many of the genes activated by Myc are related to processes of cell growth and metabolism, including protein synthesis, ribosomal biogenesis, glycolysis, mitochondrial function, and cell cycle progression (3, 11) . Most of the genes consistently found to be repressed by Myc are involved in cell cycle arrest, cell adhesion, and cell-to-cell communication (3, 10, 11) .
In this article, we describe the identification of a Myc target that is specifically repressed in Myc-transformed cells and, conversely, has a strong potential to specifically inhibit cell transformation by Myc. The gene, termed BASP1 (or CAP , encodes a 25-kDa acidic protein that was originally isolated as a membrane and cytoskeleton-associated protein from rat and chicken brain (12, 13) , but is also expressed in other tissues. The BASP1 protein is implicated in neurite outgrowth, maturation of the actin cytoskeleton, and organization of the plasma membrane (14) , but its precise biochemical function is unknown. The protein binds to calmodulin, is a substrate of protein kinase C and N-myristoyltransferase, and shares several distinctive biochemical and biophysical properties with the cytosolic growth-associated proteins GAP-43 and MARCKS (13) (14) (15) . Intriguingly, BASP1 was also found as a nuclear factor regulating the transcriptional activity of the Wilms' tumor suppressor protein WT1 (16, 17) . Our results show that (i) the BASP1 gene is consistently down-regulated in myc-transformed cells and (ii) the BASP1 protein is a strong inhibitor of myc-induced oncogenesis, defining this protein as a potential tumor suppressor.
Results

BASP1 Gene Expression Is Specifically Suppressed in Myc-Transformed
Cells. We have previously established avian cell lines conditionally transformed by doxycycline-controlled v-myc alleles (18) , displaying differential gene expression of putative Myc target genes like the strongly-activated WS5 gene that was fully characterized recently (19) . One of the original partial cDNA clones (VCB2) isolated in these screens corresponded to a gene that was strongly suppressed in Myc-transformed quail embryo fibroblasts (QEFs) (18) . We have now completely characterized this gene representing the avian homolog of the murine and human BASP1 genes encoding the neuronal brain acid-soluble protein 1 (13) . Northern analysis showed that expression of the 2-kb BASP1 mRNA is abundant in normal chicken embryo fibroblasts (CEFs) or CEFs transformed by the NK24, ASV17, or Rous sarcoma virus (RSV) retroviruses carrying the v-fos, v-jun, or v-src oncogenes, but is specifically suppressed in CEFs transformed by the MC29 or MH2 retroviruses carrying the v-myc or v-myc/v-mil oncogenes (Fig. 1A) . Specific suppression was also observed in the v-myc-and v-myc/v-miltransformed quail cell lines Q8 and MH2A10, but not in normal QEFs or QEFs transformed by v-jun (VJ) (Fig. 1 A) . The specific This article is a PNAS Direct Submission.
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down-regulation of BASP1 in Myc-transformed cells was also observed at the protein level. The BASP1 protein with an apparent M r of 58,000 was detectable in normal QEF and VJ cells, but not in Q8 or MH2A10 cells (Fig. 1B) . The specificity of BASP1 suppression in Myc-transformed cells is corroborated by comparison with the expression pattern of another gene (BRAK) isolated in our screens for putative Myc targets. BRAK represents the chicken homolog of the human CXCL14 chemokine gene (20) , and its expression is suppressed at the mRNA and protein level in all transformed fibroblasts, irrespective of the transforming agent ( Fig.  1 A and B) . We have also analyzed the dynamics of transcriptional down-regulation of BASP1 by using the conditional cell transformation system described above. Conditional activation or deactivation of the v-myc oncogene correlates directly with deactivation or activation, respectively, of the BASP1 gene in a fully-reversible pattern, indicating a close molecular link between the mutuallyexclusive expression of these genes (Fig. 1C) .
Structure of the Chicken BASP1 Gene and Protein. Alignment of the 982-bp chicken BASP1 cDNA sequence and the 190-bp VCB2 sequence with the chicken genome database confirmed that VCB2 represents the 3Ј end of the chicken BASP1 gene that encodes a 244-aa protein ( Fig. 2A) . The sequence of the first 153 bp of the chicken BASP1 cDNA was not present in the database, suggesting that this sequence belongs to a yet-unidentified exon of the BASP1 gene. This idea was corroborated by Northern analysis showing that the 153-bp segment recognized the same mRNA as a probe derived from the coding region (Fig. 2B) . The 153-bp probe was also used to screen a genomic library leading to the isolation of a 793-bp SmaI fragment. Sequence analysis (GenBank accession no. EU888907), transcription start site mapping (Fig. 2C) , and partial overlap with a contig from the chicken genome (GenBank accession no. at day Ϫ6, the drug was removed, readded at day 0, and removed again at day 6. RNAs were isolated before removal or addition of the drug and at the intermediate time points indicated. Filters in A and C were hybridized with 32 P-labeled cDNA probes specific for chicken BASP1 or BRAK, v-myc, or quail GAPDH. Sizes of the mRNAs were: BASP1, 2.0 kb; BRAK, 1.8 kb; MC29, 5.4 kb; MH2, 5.3/2.3 kb; c-myc, 2.3 kb; v-myc, 1.9 kb; GAPDH, 1.4 kb. NW001471639) revealed that the isolated fragment contains the entire untranslated exon 1 of chicken BASP1 that is separated from exon 2 by an intron of Ϸ58 kbp. A 511-bp 5Ј DNA segment extending into exon 1 was inserted into a luciferase reporter plasmid (Fig. 2 A) . The construct was transfected into normal QEFs or the cell lines QEF/MC29 or VJ transformed by v-myc or v-jun, respectively (Fig. 2D ). The analysis showed that the BASP1 promoter was specifically down-regulated in v-myc-transformed cells, in accordance with the BASP1 mRNA expression profile. Further dissection of the regulatory region revealed that a 135-bp segment from the 5Ј end of exon 1 is sufficient to mediate transcriptional activation in normal cells and suppression in Myc-transformed cells. This segment contains 2 essential binding sites for transcription factor Sp1, and ChIP showed that Sp1 and Myc occupy this minimal regulatory region (Fig. S1 ).
An alignment of the amino acid sequences of the chicken BASP1 protein and the human and mouse homologs (Fig. 2E) revealed extensive sequence similarities, particularly in the N-terminal domain encompassing a myristoylation site, a calmodulin binding region, and a putative nuclear localization signal (14, 15) . Another conserved feature is a large acidic region, presumably causing the anomalous electrophoretic mobility of BASP1 proteins in SDS/ PAGE (12, 13) . The 244-aa chicken BASP1 protein exhibits a theoretical isoelectric point of 4.66, a calculated M r of 25,438, and an apparent M r of 58,000 (Fig. 1B) .
Myc-Induced Cell Transformation Is Specifically Inhibited by BASP1.
The specific suppression of BASP1 gene expression in v-myctransformed cells prompted us to test whether constitutively expressed BASP1 interferes with Myc function. The plasmid constructs pRCAS-MC29 and pRCAS-ASV17 specify replicationdefective oncogenic retroviruses that encode Gag-Myc (p110 gag-myc ) or Gag-Jun (p83 gag-jun ) hybrid proteins, respectively (Fig. 3A) . They were used to engineer bicistronic vectors by inserting an internal ribosome entry site (IRES) followed by the coding regions of BASP1, v-mil, or BRAK, allowing simultaneous expression of v-myc or v-jun and the second gene from the same retroviral genome. Protein expression in QEFs transfected with these constructs was analyzed by immunoprecipitation or immunoblotting, confirming synthesis of the exogenous proteins specified by the particular vector. The expression pattern of the endogenous p52 c-myc , p42 c-jun , p12
BRAK , and p58 BASP1 proteins is in agreement with the known negative autoregulation of c-Myc and c-Jun proteins by their viral counterparts (21) and with the suppression of BRAK and BASP1 in v-myc-transformed cells (compare Fig. 1 ), respectively. Specifically, endogenous p58
BASP1 is expressed at high levels in normal QEFs or QEFs transformed by RCAS-ASV17, but suppressed in QEFs transformed by RCAS-MC29 or RCAS-MC29-IRES-vMil. QEFs transfected with pRCAS-MC29-IRES-BASP1 or pRCAS-MC29-IRES-BRAK contain exogenous BASP1 or BRAK proteins, equal in size to their endogenous counterparts (Fig. 3B) . Transfection of QEFs with the pRCAS-MC29 construct led to efficient cell transformation monitored by focus formation (Fig.  3C) . Coexpression of Myc and Mil oncoproteins from the pRCAS-MC29-IRES-v-Mil construct enhanced focus formation as reported (21) , and coexpression of BRAK did not interfere with the transforming capacity of Myc. Intriguingly, coexpression of Myc and BASP1 from pRCAS-MC29-IRES-BASP1 did not induce focus formation (Fig. 3C) . The reduced level of p110 gag-myc in cells transfected with this construct (Fig. 3B) is presumably caused by their nontransformed state involving a lower rate of protein synthesis, because it has been observed for the expression of a nontransforming mutant Myc protein (8) . The specificity of inhibition of Myc-induced cell transformation by BASP1 was strongly corroborated by the lack of inhibition of Jun by BASP1, as demonstrated by equal efficiency in cell transformation by pRCAS-ASV17 and pRCAS-ASV17-IRES-BASP1 (Fig. 3C) . To confirm these observations, QEF were transfected with replication-competent RCAS constructs expressing BASP1 or BRAK (Fig. 4A) , or with the empty vector, and passaged several times. The cells were then transfected with the nonviral Myc expression vector pRc-Myc (Fig. 4A) , or with the empty pRc vector, and transformation was monitored by focus formation (Fig. 4B) . Efficient focus formation was observed for cells preinfected with the RCAS or RCAS-BRAK viruses, whereas cells preinfected with RCAS-BASP1 were almost completely resistant to v-myc-induced transformation (Fig. 4B) (Fig. S2) . Overexpression of BASP1, BRAK, and v-Myc proteins from the RCAS or pRc vectors was confirmed by immunoblotting (Fig. 4B ). In contrast to the experimental design in Figs. 1 and 3 , v-Myc expression did not spread through the whole culture; hence endogenous BRAK and BASP1 proteins were detectable in the total cell extract.
To test whether ectopic BASP1 expression can also interfere with established Myc-induced cell transformation, the fully transformed cell line QEF/Rc-Myc was transfected with the pRCAS, pRCAS-BASP1, or pRCAS-BRAK vectors, and the cultures were passaged several times. As expected, endogenous BASP1 and BRAK proteins were not detectable in these cells, whereas the ectopicallyexpressed proteins were efficiently overexpressed (Fig. 4C) . The presence of exogenous BRAK did not interfere with the transformed phenotype of QEF/Rc-Myc cells, whereas ectopic BASP1 expression led to a more flattened morphology and a reduced capacity of these cells to grow in semisolid medium (Fig. 4C) . Hence, BASP1 can also partially interfere with established transformation.
To rule out that ectopic expression of BASP1 by itself effects morphology, proliferation, or viability of cells, BASP1 overexpressing cells were compared with normal or v-myc-transformed cells (Fig. S3 A-C) . No significant differences between BASP1 overexpressing and normal cells were found. Both endogenous and ectopic BASP1 proteins were distributed in cytoplasmic and nuclear localizations (Fig. S3D ), in agreement with previous reports (16, 17) . Efficient knockdown of BASP1 expression by transient siRNA nucleofection in the chicken DF-1 cell line (Fig. S3E) did not lead to significant changes in cellular morphology or proliferation, nor to changes in c-myc expression.
BASP1 Prevents Myc Target Gene Activation.
To test whether ectopic BASP1 interferes with the activation of direct Myc target genes like WS5 or Q83 (19, 22) , QEFs were transfected with pRCAS-MC29, pRCAS-MC29-IRES-BASP1, or pRCAS-BASP1. Normal QEF or QEF/RCAS-BASP1 cells did not contain WS5 or Q83 mRNAs, whereas high levels were found in the Myc-transformed QEF/ RCAS-MC29 cells, in agreement with previous reports (19, 22) . Cells transfected with the bicistronic construct pRCAS-MC29-IRES-BASP1 contained no or low levels of WS5 or Q83 mRNAs, indicating an inhibitory effect of BASP1 on target gene activation by Myc (Fig. 5A) . Accordingly, expression of BRAK was abolished only in the RCAS-MC29-transformed cells. The Myc-transformed cell line QEF/MC29 was transfected with a luciferase reporter construct containing the WS5 promoter (pWS5-LUC) and a pRc expression vector containing the BASP1 coding region (pRc-BASP1) or engineered deletion mutants (Fig. 5B) . Ectopic WT or mutant BASP1 protein expression was monitored by immunoblotting (Fig. 5C ). The promoter analysis showed that ectopic WT BASP1 expression efficiently interferes with Myc-mediated transcriptional activation (Fig. 5D) . Deletion of 10 amino acid residues from the N-terminal BASP1 domain (⌬MN) almost abrogated this inhibitory function, whereas even large deletions in other regions (⌬PS, ⌬RP, ⌬CT) had no significant effect. As a control, ectopic expression of the transcription factor C/EBP␣ led to strong promoter activation (Fig. 5D ), in agreement with our previous identification of binding sites for Myc and C/EBP␣ on the WS5 promoter (19) . In normal CEFs containing low levels of C/EBP␣ (19) , ChIP analysis revealed association of c-Myc, BASP1, and Sp1 with the WS5 promoter (Fig. S1D) . The mutant BASP1 proteins (Fig. 5B) were also expressed from RCAS vectors (compare Fig.  4B ) and tested for their potential to interfere with Myc-induced focus formation, including 2 constructs in which amino acids 1-11 or 12-244 from BASP1 were fused to the GFP. The results indicate that the N-terminal region of BASP1 is essential for its inhibitory function (Fig. 5 E and F) . Further mutational analysis revealed that complete integrity of the N-terminal region including the myris- toylation site (G) and putative nuclear localization (KKKK) signal is necessary for the full potential of BASP1 to inhibit target promoter activation and cell transformation (Fig. S4) . To test whether the inhibitory functions of BASP1 were mediated by direct interaction with the Myc protein, coimmunoprecipitation experiments were carried out. Under conditions that allow detection of Myc/Max interaction in normal fibroblasts, direct interaction between BASP1 and Myc could not be detected (Fig. S5) .
Discussion
The oncogenic capacity of the Myc protein is based on its biochemical function as a regulator of gene expression, exhibiting both gene-activating and gene-repressing potential. Because transcriptional control by Myc involves either activation or repression of genes, regulation of both growth-promoting and -inhibiting targets is implicated in establishing the Myc-induced oncogenic phenotype (3, 10, 11) . The specific identification of such genes is severely complicated by the large number of direct or indirect putative Myc targets identified by extensive expression profiling or genomic DNA binding studies (3) . Furthermore, the possible role of Myc as a coactivator or corepressor of other transcriptional regulators and the recent evidence that some functions of Myc may be independent of Max or E-box binding even amplify the range of possible Myc targets (3, 8, 9, 23, 24) .
We have been aiming at the isolation of genes that are specifically regulated by oncogenic transcription factors and display either oncogenic or tumor-suppressive potential. Following this approach, we have recently described the isolation of the direct Jun-activated targets TOJ3 (MSP58) and JAC, both displaying intrinsic oncogenic activity (25, 26) , and the direct Myc-activated target WS5, related to human melanoma glycoprotein genes showing cell-transforming potential (19) . The BASP1 gene now identified as a specific Myc target has several unique properties. Repression of BASP1 gene transcription is highly specific for Myc-transformed cells and not a general cellular response to oncogenic transformation. The kinetics of immediate BASP1 repression and reactivation in a conditional Myc transformation system also point to a specific molecular link between oncogenic Myc and BASP1 transcriptional repression. However, the 5Ј control region of BASP1 that is sufficient to mediate promoter repression in reporter gene assays does not contain a typical Myc binding site. As discussed above, this does not rule out control by Myc, because transcriptional repression by Myc may occur independently of E-box binding via protein-protein interactions on the core promoter as it has been reported for several genes suppressed by Myc (3, 9) .
The most striking property of BASP1 is its potential to block the initiation of Myc-induced cell transformation, when the repression by Myc is circumvented by ectopic expression of BASP1 from retroviral vectors. Again, this is a highly specific effect, because ectopic expression of BASP1 does not inhibit cell transformation by the jun or src oncogenes. Furthermore, ectopic expression of the transformation-sensitive BRAK gene does not interfere with Mycinduced cell transformation. The inhibitory effect was independently demonstrated by simultaneous expression of Myc and BASP1 proteins from a bicistronic vector or preinfection of cultured cells with a BASP1 vector before they were challenged with oncogenic Myc. Both routes prevented cell transformation by the Myc protein almost completely. Subsequent introduction of ectopic BASP1 into cells after Myc-induced transformation has been fully established leads to a significant, but only partial, reversion of the transformed phenotype.
The BASP1 protein was originally isolated as a membrane-and cytoskeleton-associated protein from rat and chicken brain. Although the protein is expressed in various tissues, it is particularly abundant in neurons during brain development and implicated in neurite outgrowth (14) . BASP1 is a member of the family of growthand motility-associated proteins, including GAP-43 and MARCKS, implicated in the regulation of actin dynamics and membrane structure (27) . These proteins share characteristic properties, including N-terminal myristoylation, facilitating association with lipid rafts of the plasma membrane, and a basic effector domain that binds acidic phospholipids including phosphatidylinositol-4,5-biphosphate, Ca 2ϩ -calmodulin, and actin filaments. These interactions are presumably regulated by protein kinase C-mediated phosphorylation (14) . Intriguingly, BASP1 was also reported to be located in the nucleus of mouse and human cells of various tissues (16, 17, 28) , and it was proposed that myristoylated and nonmyristoylated forms of the protein have different subcellular locations. It was reported that the nuclear form of BASP1 associates with the WT1 transcription factor and attenuates its transcriptional activity (16, 17, 29) . WT1 is associated with tumor suppressive and oncogenic potential, and BASP1 was proposed to function as a cosuppressor for WT1 (29) . The exact biochemical function of BASP1 is unknown, and it remains to be determined which molecular mechanisms lead to inhibition of Myc-induced oncogenesis by ectopic expression of BASP1 and by which precise mechanism endogenous BASP1 expression is shut off in Myc-transformed cells. Elucidation of the apparently mutually-exclusive functions of BASP1 and oncogenic Myc may facilitate the further delineation of the oncogenic pathways induced by this oncoprotein.
Materials and Methods
Cells and Retroviruses. Cell culture, DNA transfection, and transformation of CEFs and QEFs were performed as described (26) . The avian retroviruses ASV17, NK24, MC29, MH2, and RSV, and the established quail cell lines Q8, MH2A10, VJ, and Q/tM ON were used (18, 19, 21, 30) . The retroviral constructs pRCAS-MC29 and pRCAS-MC29-IRES-v-Mil have been described (21) . pRCAS-ASV17 was constructed by replacing the 1,248-bp v-myc coding region of pRCAS-MC29 with the 861-bp v-jun coding region of ASV17. To generate pRCAS-MC29-IRES-BASP1, pRCAS-MC29-IRES-BRAK, and pRCAS-ASV17-IRES-BASP1, the coding regions of chicken BASP1 or BRAK were amplified by PCR from CEF total cDNA and inserted into the NcoI/BamHI sites of the adaptor plasmid pA-CLA12NCO as described (21), yielding pA-BASP1 and pA-BRAK. BASP1 or BRAK were excised from the adapter constructs as XbaI fragments and inserted into pIRES (BD Biosciences). EcoRI/NotI (blunt-ended) fragments containing either IRES-BASP1 or IRES-BRAK were then ligated into the unique KpnI sites (blunt-ended) of pRCAS-MC29 or pRCAS-ASV17, respectively. Derivatives of the adapter pA-BASP1 plasmid were engineered by deleting 288-bp PvuII/StuI (⌬PS), 324-bp RsaI/PvuII (⌬RP), and 34-bp CviQI/NcoI (blunt-ended) (⌬MN) fragments followed by religation. To construct pA-⌬CT, the 90-bp StuI/BamHI fragment was replaced by an oligonucleotide containing a stop codon (5Ј-GGTAAGGCCATTACGGCCG-3Ј). For construction of pA-GFP-⌬MN, a 711-bp NcoI/BsrGI(blunt-ended) fragment from pIRES2-EGFP (Clontech) was ligated together with a 718-bp amplified fragment from pA-BASP1 into the NcoI/SalI sites of pA-CLA12NCO, resulting in fusion of codons 1-239 (GFP) with codons 12-244 (BASP1). To construct pA-NT-GFP, an oligonucleotide containing the BASP1 codons 1-11 (5Ј-CATGGGAGGCAAACTGAGCAA-GAAGAAGAAGGGG-3Ј) was inserted together with a PCR fragment containing the GFP codons 2-239 into NcoI/SalI-cut pA-CLA12NCO. To construct pRCAS-BASP1, pRCAS-BASP1 derivatives, and pRCAS-BRAK, ClaI fragments from pA-BASP1, pA-BASP1 derivatives, or pA-BRAK were inserted into the pRCAS-BP vector as described (26) . Colony assays and focus assays were done as described (26, 30) . To monitor focus formation, cells were fixed with ethanol and incubated for 30 min in Giemsas eosin methylene blue solution diluted 1:10.
DNA Cloning and Nucleic Acid Analysis. Molecular cloning, DNA sequencing, Northern analysis, and primer extension have been described (21, 26) . To isolate a 793-bp SmaI genomic fragment containing the 281-bp chicken BASP1 exon 1 including 379 bp of 5Ј-untranscribed region (GenBank accession no. EU888907), a genomic library was screened by using a cDNA probe corresponding to nucleotides 1-153 of the chicken BASP1 mRNA sequence (GenBank accession no. NM204116). BRAK was isolated by subtractive hybridization as described (26) using cDNAs synthesized on poly(A) ϩ RNA from normal CEFs, followed by hybridization with total mRNA from ASV17-transformed CEFs. The subtracted probe was used to screen a CEF cDNA library.
Transactivation Analysis. To construct pLUC-BASP1, a 511-bp SmaI/SacII (bluntended) segment from the genomic fragment was inserted into the pGL3-Basic vector (Promega). pLUC-WS5 was generated by transferring the 282-bp HindIII/ XbaI (blunt-ended) fragment of pCAT-WS5 (19) into the HindIII (blunt-ended) site of pGL3-Basic. The expression vector pRc-C/EBP␣ has been described (19) . To construct pRc-BASP1 and mutant derivatives, the NcoI (blunt-ended)/XbaI inserts from adapter constructs were transferred into pRc/RSV cut with HindIII (bluntended)/XbaI. DNA transfer into cells by nucleofection was done as described (19) using liposome solution V and electroporation program T-20.
Protein Analysis. A 15-mer peptide corresponding to the C-terminal residues 229 -243 of the chicken BASP1 protein (H2N-SEAPATNSDQTIAVQ-COOH) and full-length recombinant BASP1 or BRAK proteins were used to generate rabbit polyclonal antisera. Immunoblotting was done as described (18, 25) . Immunoprecipitation of 35 Smethionine-labeled proteins and SDS/PAGE were done as described with antisera directed against Myc, Mil, and Jun proteins (21) .
For additional information, see SI Text.
